Short-acting GLP-1 receptor agonists such as exenatide immediate-release (Byetta) and lixisenatide (Adlyxin) must be administered within 60 minutes before meals
Furthermore, the risks of individual cancers did not show an increase in the tirzepatide group compared to either the pooled or individual control groups
If the gallbladder was removed due to acute cholecystitis, gallstone pancreatitis, or biliary complications, it is prudent to ensure complete recovery and resolution of any inflammatory processes before initiating weight loss therapy
GLP-1 medications may cause serious side effects
Disclosures: Joseph Ahn: Nothing to Disclose, Nothing to Disclose, Hyunseok Kim: Nothing to Disclose, Michael Luu: Nothing to Disclose, Alexander Kuo: Nothing to Disclose, Walid Ayoub: Intercept: Speaking and Teaching, Mirum: Grant/Research Support, GSK: Consultant, GSK: Grant/Research Support, Madrigal: Grant/Research Support, Cymabay: Consultant, Ipsen: Grant/Research Support, Zydus: Grant/Research Support, Hirsh Trivedi: Nothing to Disclose, Yun Wang: Nothing to Disclose, Aarshi Vipani: Nothing to Disclose, Tsuyoshi Todo: Nothing to Disclose, Steven Wisel: Nothing to Disclose, Todd Brennan: Nothing to Disclose, Justin Steggerda: Nothing to Disclose, Joe Schwab: Nothing to Disclose, Irene Kim: Nothing to Disclose, Kambiz Kosari: Nothing to Disclose, Neehar Parikh: Genentech: Grant/Research Support, Exelixis: Grant/Research Support, Exelixis: Consultant, AstraZeneca: Consultant, Exact Sciences: Grant/Research Support, Exact Sciences: Consultant, Fujifilm Medical: Advisor, Amit Singal: Genentech: Consultant, AstraZeneca: Consultant, Bayer: Consultant, Eisai: Consultant, Exelixis: Consultant, Merck: Consultant, Elevar: Consultant, FujiFilm Medical Sciences: Consultant, Exact Sciences: Consultant, Glycotest: Consultant, Boston Scientific: Consultant, Sirtex: Consultant, HistoSonics: Consultant, Ju Dong Yang: Nothing to Disclose 1819 LIVER TRANSPLANTATION IS THE MAJOR DETERMINANT IN ACHIEVING OVER 10-YEAR SURVIVAL FOR PATIENTS WITH EARLY-STAGE HEPATOCELLULAR CARCINOMA Joseph Ahn 1 Hyunseok Kim 2 Michael Luu 2 Alexander Kuo 2 Walid Ayoub 2 Hirsh Trivedi 2 Yun Wang 2 Aarshi Vipani 2 Tsuyoshi Todo 2 Steven Wisel 2 Todd Brennan 2 Justin Steggerda 2 Joe Schwab 2 Irene Kim 2 Kambiz Kosari 2 Neehar Parikh 3 Amit Singal 4 Ju Dong Yang 2 , 1 Mayo Clinic, 2 Cedars-Sinai Medical Center, 3 University of Michigan Medical Center, 4 UT Southwestern Medical Center Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with prognosis heavily dependent on the stage at diagnosis and treatment modalities
